Figure 3From: Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis Total cost by cost category for patients (a) <60, (b) 60–79, and (c) ≥80 years old. All values discounted and censored adjusted. Blue bar represents CHOP patients; light pink bar represents R-CHOP patients.Back to article page